Syndax Pharmaceuticals, Inc. Earnings Per Share (Basic)
Syndax Pharmaceuticals, Inc. (SNDX) reported Earnings Per Share (Basic) of -$0.55 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.55.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.48.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.78.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.70.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$3.29.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$3.72.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$2.98.
- Syndax Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$2.46, a 612.50% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.55 10-Q · filed 2026-08-04 | -$1.04 10-Q · filed 2026-08-04 | -$1.82 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.52 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2026-03-31 | -$0.48 10-Q · filed 2026-04-30 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.79 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-12-31 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.48 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.29 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.70 10-Q · filed 2025-11-03 | -$1.53 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$2.51 10-Q · filed 2025-11-03 | -$3.61 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-06-30 | -$0.83 10-Q · filed 2026-08-04 | -$1.82 10-Q · filed 2026-08-04 | -$2.90 derived: net income ÷ weighted average shares · filed 2026-08-04 | -$3.89 derived: net income ÷ weighted average shares · filed 2026-08-04 |
| 2025-03-31 | -$0.98 10-Q · filed 2026-04-30 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.06 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.86 derived: net income ÷ weighted average shares · filed 2026-04-30 |
| 2024-12-31 | -$1.09 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.87 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.72 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.98 10-Q · filed 2025-11-03 | -$1.78 derived: net income ÷ weighted average shares · filed 2025-11-03 | -$2.63 10-Q · filed 2025-11-03 | -$3.62 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | -$0.80 10-Q · filed 2025-08-04 | -$1.65 10-Q · filed 2025-08-04 | -$2.63 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.38 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$0.85 10-Q · filed 2025-05-05 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.58 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.24 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$1.00 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.74 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.38 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.98 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.73 10-Q · filed 2024-11-05 | -$1.37 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.97 10-Q · filed 2024-11-05 | -$2.59 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-06-30 | -$0.64 10-Q · filed 2024-08-01 | -$1.23 10-Q · filed 2024-08-01 | -$1.85 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$2.44 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2023-03-31 | -$0.59 10-Q · filed 2024-05-08 | -$1.21 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$1.80 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$2.42 derived: net income ÷ weighted average shares · filed 2025-03-03 |
| 2022-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$1.20 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$1.83 derived: net income ÷ weighted average shares · filed 2025-03-03 | -$2.46 10-K · filed 2025-03-03 |
| 2022-09-30 | -$0.58 10-Q · filed 2023-11-02 | -$1.21 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$1.84 10-Q · filed 2023-11-02 | -$0.24 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-06-30 | -$0.62 10-Q · filed 2023-08-03 | -$1.25 10-Q · filed 2023-08-03 | $0.37 derived: net income ÷ weighted average shares · filed 2024-02-27 | $0.01 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-03-31 | -$0.63 10-Q · filed 2023-05-08 | $1.05 derived: net income ÷ weighted average shares · filed 2024-02-27 | $0.70 derived: net income ÷ weighted average shares · filed 2024-02-27 | $0.29 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | $1.81 derived: net income ÷ weighted average shares · filed 2024-02-27 | $1.44 derived: net income ÷ weighted average shares · filed 2024-02-27 | $1.01 derived: net income ÷ weighted average shares · filed 2024-02-27 | $0.48 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.40 10-Q · filed 2022-11-03 | -$0.84 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.38 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$0.44 10-Q · filed 2022-08-08 | -$0.98 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | -$1.87 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -$1.84 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |